<bold>Background: </bold>Skin toxicity has recently been recognized as a dose-limiting toxicity of antineoplastic therapy.<bold>Discussion: </bold>We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel.